Artiva Biotherapeutics (ARTV) Cash & Equivalents (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Cash & Equivalents data on file, last reported at $86.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 185.52% year-over-year to $86.8 million in Q1 2026; TTM through Mar 2026 was $86.8 million, a 185.52% increase from a year earlier, with the FY2025 full-year figure at $26.7 million, down 33.64% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $86.8 million, up from $26.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ARTV reached as high as $123.0 million in Q3 2025 and fell as low as $26.7 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $53.9 million across 4 years, with a median of $50.9 million in 2023.
• Across the five-year window, Cash & Equivalents slumped 36.93% in 2025 and soared 185.52% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $53.5 million in 2023, then declined by 24.8% to $40.2 million in 2024, then tumbled by 33.64% to $26.7 million in 2025, then jumped by 225.08% to $86.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $86.8 million in Q1 2026, $26.7 million in Q4 2025, and $123.0 million in Q3 2025.